Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript
Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript
AKBA - Akebia Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$4.00
DETAILS
HIGH:
$4.00
LOW:
$4.00
MEDIAN:
$4.00
CONSENSUS:
$4.00
UPSIDE:
292.16%
Stock News
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.03 per share a year ago.
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights
Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million ; Q1 2026 total net product revenues of $52.0 million Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q4 2025 Akebia hosted virtual R&D Day highlighting robust kidney disease pipeline, outlining clinical trial plans and timing of expected data catalysts Patient enrollment continues to progress in praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS) Akebia to host conference call on May 7, 2026, at 8:00 a.m. EST CAMBRIDGE, Mass.
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 7 newly-hired employees options to purchase an aggregate of 208,800 shares of Akebia's common stock on April 30, 2026.
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology
CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the publication of a post-hoc win statistics analysis of all-cause mortality and hospitalization from its global Phase 3 INNO2VATE program in the Journal of the American Society of Nephrology (JASN), a leading, high-impact, peer-reviewed journal in nephrology.
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia to Host Conference Call on May 7 at 8:00 a.m. EDT CAMBRIDGE, Mass.
New Strong Sell Stocks for April 28th
EADSY, AKBA and AMTB have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2026.
Ionis Pharmaceuticals (NASDAQ:IONS) and Akebia Therapeutics (NASDAQ:AKBA) Financial Analysis
Ionis Pharmaceuticals (NASDAQ: IONS - Get Free Report) and Akebia Therapeutics (NASDAQ: AKBA - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends. Volatility and Risk Ionis Pharmaceuticals has a beta
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
CAMBRIDGE, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the first participants have been dosed in a Phase 1 clinical trial of AKB-9090, an internally developed hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor being evaluated for the treatment of cardiac surgery-associated acute kidney injury (AKI).
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
CAMBRIDGE, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P.
JPMorgan Chase & Co. Has $2.71 Million Holdings in Akebia Therapeutics, Inc. $AKBA
JPMorgan Chase and Co. lessened its holdings in Akebia Therapeutics, Inc. (NASDAQ: AKBA) by 39.8% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 994,181 shares of the biopharmaceutical company's stock after selling 658,565 shares during the quarter. JPMorgan Chase and Co. owned
Akebia Therapeutics R&D Day: Vafseo Growth Plan, Praliciguat Phase 2, New Kidney Pipeline Targets
Akebia Therapeutics (NASDAQ: AKBA) used its R&D Day presentation to outline a strategy centered on expanding its commercial anemia franchise while advancing three kidney disease pipeline programs: praliciguat in focal segmental glomerulosclerosis (FSGS), the tissue-targeted complement inhibitor AKB-097 (abribafisp) in complement-mediated kidney diseases, and AKB-9090 in cardiac surgery-associated acute kidney injury (CSA-AKI). Commercial backdrop: Vafseo growth
Akebia Therapeutics, Inc. $AKBA Shares Sold by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. cut its stake in Akebia Therapeutics, Inc. (NASDAQ: AKBA) by 94.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,872 shares of the biopharmaceutical company's stock after selling 401,894 shares during the period. Assenagon Asset Management
Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day Transcript
Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day Transcript
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 13 newly-hired employees options to purchase an aggregate of 679,900 shares of Akebia's common stock on March 31, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
CAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of biopharmaceutical leader Philip J. Vickers to its Board of Directors, effective April 1, 2026. Dr. Vickers is the President and Chief Executive Officer and a member of the Board of Directors of Solu Therapeutics, a venture-backed biotechnology company focused on creating first-in-class therapeutics utilizing a novel drug discovery platform, and he has held senior leadership positions at several early-stage biotechnology companies as well as global pharmaceutical companies.
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026
CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will host a virtual R&D Day on Thursday, April 2, 2026 at 10:00 AM EDT.
Is the Options Market Predicting a Spike in Akebia Therapeutics Stock?
Investors need to pay close attention to AKBA stock based on the movements in the options market lately.
Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript
Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P.
Price Targets
Akebia price target lowered to $4 from $6 at Piper Sandler
$4.00
(was $1.38)
Allison Bratzel
·
Piper Sandler
Akebia price target raised to $6 from $5 at H.C. Wainwright
$6.00
(was $1.98)
Ed Arce
·
H.C. Wainwright
Akebia Therapeutics (AKBA) Stock: $7 Price Target And Buy Rating
$7.00
(was $2.65)
Serge Belanger
·
Needham